

Investor Relations Brief

2024
8 August

益生菌 BNRThin S

功能性益生菌 BNRThin S



品牌代言人
- 金喜善

Business Division Progress Report

Molecular Diagnostics

On July 16, the Diagnostic Business and Marketing Department obtained European CE IVDR certification for four models of the world-class real-time PCR equipment, ExiCycler™ V5. This equipment significantly reduces testing time and power consumption. The ExiCycler™ V5 is expected to be widely used in various fields, including molecular diagnostics, mRNA and microRNA (miRNA) expression analysis, quantitative and qualitative testing, and new drug candidate selection. By applying patented nanomaterial technology, this product greatly shortens testing time and reduces electricity usage, significantly contributing to carbon emission reduction. Through the global distribution of next-generation PCR equipment, the Company aims to lead in global carbon emission reduction and creating ESG standard cornerstones for the industry.

Additionally, on July 15, the company launched the DTC (Direct-to-Customer) genetic testing kit 'Gene2Life' on its online sales website. Among the 14 institutions that have obtained domestic DTC certification, the company is the only one conducting genetic testing based on domestic technology. "Gene2Life," based on proprietary technology, does not acquire any genetic information other than the intended genetic test results, contributing to the creation of a reliable precision medicine environment for customers. Bioneer plans to continue expanding its research and business through collaborations with various industrial sectors.

CosmeRNA

The CosmeRNA business team has signed an exclusive supply contract for hair loss cosmetic products with Gencell Pharma, a hospital distribution company in Colombia, marking its first entry into the South American market. Additionally, in September, the team will participate in the 2024 European Academy of Dermatology and Venereology (EADV) in Amsterdam, Netherlands, where they will promote CosmeRNA to global dermatology and aesthetic medicine professionals. During this event, as in the 2023 EADV, the team will showcase the Iron-qPCR™ device to demonstrate genetic testing for hair loss.

Regarding B2B business, the first order from the United Arab Emirates has recently been received, and supply to Atlas Medical is set to begin in August. The supply timeline may vary depending on local certification and registration schedules in each country. The Team is actively working to expedite these schedules as much as possible.

AceBiome

AceBiome's sales for the first half of 2024 amounted to 144.5 billion KRW, reflecting a growth of approximately 32% compared to the same period last year. The Duty-free shop on Korean Airline, where the Company started selling products in June, received additional orders, indicating positive initial customer feedback. Additionally, the company plans to carry out a complete brand renewal for BNRThin in August.

The company has officially entered the 21 billion USD KRW Chinese probiotics market by opening an "BNR Mall" (the Company's D2C "Direct to Consumer" Website) on China's prominent social commerce platform, Xiaohongshu. Concurrently, the advertising contract with Kim Hee-sun has been expanded to include not only China but also Hong Kong and Taiwan. Based on this, the company intends to gradually respond to the demand in the Greater China region.

siRNAgen Therapeutics

siRNAgen Therapeutics is currently preparing the SRN-001 Phase 1a clinical trial report. This includes discussions on the interpretation of statistically processed data and conducting non-public meetings with external clinicians. Based on these activities, the company plans to commence the drafting of the clinical trial report.

In addition to these preparations, siRNAgen Therapeutics is actively introducing SRN-001 clinical results and SAMiRNA-based technology to various stakeholders. The company participated in the 'InterBiz Bio-Partnering & Investment Forum 2024' held from July 3 to 5, where it showcased its advancements to domestic pharmaceutical companies. Furthermore, siRNAgen Therapeutics is gearing up to present its findings to international pharmaceutical companies as the clinical report publication approaches.

Participation in Academic Events

27th Korean Society of Clinical Microbiology

26th Seoul Asan Medical Center Pulmonology Course

Bioneer participated in the “27th Korean Society of Clinical Microbiology conference”, where they promoted products such as the IRON-qPCR™, optimized for syndromic diagnostics, capable of detecting up to 40 targets within 40 minutes, as well as RFIA, CRE, Tsutsugamushi, and STI Kits. Bioneer promoted our products and networked with domestic and international diagnostic experts.

Additionally, at the “26th Asan Medical Center Respiratory Medicine Conference Exhibition”, they promoted key respiratory products to pulmonology specialists and clinical microbiologists. These included the RFIA Kit, which can detect TB, MDR, and XDR simultaneously, and the RV Kit, which can detect COVID-19, Influenza, and RSV, thus enhancing brand awareness.



Roundtable Hosted by “Doctors Without Borders”

Bioneer Plans to Address the Unmet Needs of Developing Countries

Chairman Han-oh Park of Bioneer participated in a roundtable held at the Korean National Assembly on July 1, titled “Improving Global Health Diagnostics Equity and Korea's Role.” During this event, hosted by “Doctors Without Borders”, he discussed and presented solutions to bridge the global diagnostics gap. The event brought together officials from government agencies such as the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, as well as representatives from international health organizations and diagnostic companies.



Chairman Park stated, “Bioneer was the first company in Korea to develop PCR products using domestic technology and supply them to over 150 educational institutions in Korea.” He emphasized the urgent need to address the lack of effective diagnostic tools for pediatric tuberculosis, which results in the death of 170,000 children annually. He also expressed Bioneer's commitment to working with Doctors Without Borders to meet the unmet healthcare needs of developing countries and called for strong support from relevant organizations and government departments.

Additionally, Chairman Park highlighted Bioneer's achievements, including the rapid development of an anthrax detection solution within six months, in response to the 2002 World Cup security concerns following the 9/11 attacks. This solution, which typically takes eight years to develop, was successfully provided to the government and is still in use today. He also noted that during the 2009 H1N1 flu pandemic, Bioneer developed a diagnostic product that received approval from the Ministry of Food and Drug Safety, making Korea the only country to conduct pre-prescription PCR diagnostics for Tamiflu, thus leading the promotion and popularization of PCR technology domestically and internationally.



Bioneer News

MedLab Asia 2024

Consultations with Over 200 Companies



Bioneer participated in “Medlab Asia 2024”, held in Bangkok, Thailand, from July 10 to 12. Focusing on IRON-qPCR™ and ExiStation™, they engaged in networking with distributors and sought out new partners. This exhibition is one of the most significant medical laboratory and healthcare exhibitions in the ASEAN region, featuring over 350 exhibitors this year. Bioneer held meetings with more than 200 companies from countries including Australia, Singapore, Thailand, the Philippines, Indonesia, and Malaysia to explore opportunities for international market expansion.

